You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Radionuclide Therapy for Neuroendocrine Malignancies

ID: 12-13 aoû 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
K.Y. Gulenchyn, X. Yao, S.L. Asa, S. Singh, C. Law, Radionuclide Therapy Neuroendocrine Tumours Expert Panel

Patient Population

Neuroendocrine cancer patients who are inoperable, or have residual disease following surgery or other ablative therapy, or have metastases.

Intended Guideline Users

Nuclear medicine physicians, medical oncologists, surgeons, and pathologists who are involved in the treatment of the above-targeted patients.

Research Question(s)

  1. What are the effects of the eight commonly used and studied therapeutic radiopharmaceuticals described in Table 1 in patients with different types of neuroendocrine malignancies?
  2. Which one of the eight therapeutic radiopharmaceuticals is most effective in improving clinical outcomes (i.e., tumour response, duration of tumour response, overall survival [OS] time/rate, progression-free survival [PFS] time/rate, biochemical response, and quality of life [QOL]) in the above patients?
  3. What are the toxicities for each therapeutic radiopharmaceutical?
pdf download Summary (PDF) (177.5 Ko)
pdf download Full Report (PDF) (819.29 Ko)